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Abstract
Purpose of Review Severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) is identified from Wuhan, China, and has
spread almost worldwide. Recently, the newly identified SARS-CoV-2 has been confirmed to kill millions of people worldwide
and is dangerous to society health, survival, and livelihood. The people with cardiovascular problems are noticed as most
common patients of coronavirus disease 2019 (COVID-19). There is a greater risk of mortality and morbidity in these patients
than other patients of COVID-19. In the heart, expressed angiotensin-converting enzyme 2 (ACE2) and response effect of
hyperactivity with angiotensin II associated to the renin-angiotensin mechanism are key factors of hypertension, atherosclerosis,
and congestive heart failure.
Recent Findings Mortality rates have been observed about 10.5% cases in patients with cardiovascular disease; however, a
mortality rate of 52% was recorded in patients with heart failure, while 12% recovered ultimately. The occupancy of intense
injury controlled by troponin elevation was a noteworthy factor in relation to mortality. Among 187 patients infected with SARS-
CoV-2, about 35%were diagnosed with cardiovascular disease (CVD) history and 28%with raised troponin. Troponin elevation
was identified more frequently (55%) in patients with cardiovascular diseases. Mortality rate in patients without cardiovascular
diseases and normal troponin was 7.6%, normal troponin and cardiovascular disease with 13.3%, augmented troponin and
without cardiovascular disease 37.5%, however 69.4% among cardiovascular disease and advanced troponin.
Summary The study reflected a significant association of case fatality rate (CFR) to COVID-19 patients with cardiovascular
diseases which supposed to be the most common dangerous risk factor and health challenge during the current pandemic
situation.
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Introduction
Severe acute respiratory syndrome coronavirus-2 (SARS-
CoV-2) is a member of RNA family beta human coronavirus
identified in Wuhan City, China. The case of COVID-19
(coronavirus disease 2019) was first admitted in a center on
12 December 2019, and the primary phase of patients was
first recognized on 6 January 2020. Even the human-to-
human transmission was viewed in mid-January 2020 [1].
The occurrences of 3rd and 4th stages of transmission have
been accounted since 4 February 2020 [2]. In Wuhan, China
has uncovered a scene of atypical pneumonia achieved by
SARS-CoV-2 [3, 4]. Since December 2019, contamination
has transmitted the nation over and universally [1, 5]. The
European Center for Ailment Prevention and Control
showed that, beginning on 2 March 2020, more than
89,000 COVID-19 cases have been accounted all around
the world, from all zones of China and 66 countries globally
[3]. These beta coronaviruses belong to seven species and
caused infections in humans. In the four types of
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coronavirus, predominant symptoms such as little bit phlegm
are observed, but in SARS (severe acute respiratory syn-
drome), MERS (Middle East respiratory syndrome), and
COVID-19, symptoms result in potentially fatal illnesses.
Cardiometabolic request related with fundamental contami-
nation combined with hypoxia symptoms because of intense
respiratory ailment may decrease myocardial oxygen
request—which gracefully linked and may lead to prompt
intense myocardial infarction. Expanded shear worry be-
cause of fundamental irritation just as expanded coronary
blood stream can prompt intense myocardial-localized ne-
crosis. The prothrombotic milieu made by foundational irri-
tation further builds the hazard, i.e., coronary thrombosis and
plaque break. Due to complete illness, the electrolyte can be
imbalanced and may lead to precipitation of arrhythmias
while this condition can be observed in the patients of cardi-
ac disorder. The action of renin-angiotensin-aldosterone
mechanism with COVID-19 may cause issue of hypokale-
mia in COVID-19 patients and vulnerability of enhanced
tachyarrhythmias to swift case fatality rate and mortality [6].
Cardiovascular Mechanism and SARS-CoV-2
Although the primary target of SARS-CoV-2 is the respira-
tory tract for COVID-19, the cardiovascular mechanism can
be involved in many other ways (Fig. 1) [7, 8]. The infection
of SARS-CoV-2 is developed by the spike protein activation
by angiotensin-converting enzyme 2 (ACE2) receptors in
humans to the Trans-Membrane Protease Serine-2
(TMPRSS2) [9]. Angiotensin-converting enzyme catalyzes
the arrangement of angiotensin II (Ang II) and accordingly
plays a key job in cardiorenal guideline and circulatory strain
control. The overactivity of renin-angiotensin framework
contributes to the pathophysiology of hypertension and car-
diovascular breakdown that is reflected in utilization of ACE
inhibitors during the treatment of these conditions [10].
ACE2 is known to be profoundly communicated in the hu-
man heart and may act to restrict the movement of the renin-
angiotensin framework by changing over Ang II to the va-
sodilator Ang I-7 [11]. Moreover, ongoing creature informa-
tion recommend that ACE2 can adjust heart contractility,
stifle cardiovascular Ang II levels, and down-direct hypox-
ia-instigated support of apoptotic qualities highlighting a job
for ACE2-inferred peptides in the guideline of cardiovascu-
lar capacity [12]. It was expressed that overactivity of the
renin-angiotensin framework is involved in the pathophysi-
ology of incessant cardiovascular breakdown [13]. A viral
disease can intensely influence the cardiovascular frame-
work, causing an expanded danger of intense coronary con-
ditions, myocardial discouragement prompting cardiovascu-
lar breakdown, or arrhythmias and myocarditis/pericarditis
[14]. Patients with cardiovascular malady including HF
(heart failure) are especially defenseless against flu and other
infective ailments of the upper and lower respiratory parcel
that cause a more serious danger to them [15, 16]. In any
case, the effect of the ongoing flare-up of COVID-19
brought about by the infection SARS-CoV-2 in patients with
previous cardiovascular horribleness or the danger of cardio-
vascular entanglements has not been widely assessed [17]. In
this way, the ACE2 was exceptionally communicated in
pericytes of grown-up human hearts, which showed an
Fig. 1 Cardiovascular problems
in patients infected by SARS-
CoV-2
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inborn helplessness of the heart to the SARS-CoV-2 disease
[18]. Patients with essential cardiovascular breakdown ill-
ness showed expanded articulation of ACE2 and might have
a high chance of coronary episode, advancing to extreme
condition after contamination [19].
In the lung, mainly type II alveolar cells expressed
angiotensin-converting enzyme 2 and the main portal of en-
try appears [20]. In the heart, expressed angiotensin-
converting enzyme 2 and response effect of hyperactivity
with angiotensin II associated to the renin-angiotensin mech-
anism are key factors of hypertension, atherosclerosis, and
congestive heart failure [21]. Notwithstanding the lungs and
heart, angiotensin-converting enzyme 2 is communicated in
the intestinal epithelium, vascular endothelium, and kidneys,
giving a mechanism to the multi-organ dysfunction that can
be seen along with SARS-CoV-2 contamination [21, 22].
The morbidity and mortality rate is increased with increasing
evidence linking COVID-19 to heart disease and leads to
injury in the lung, arrhythmia, and myocardial infarction
[7, 8]. The consecutive inflammations and highly extreme
types of SARS-CoV-2 are portrayed by acute routinely in-
flammatory reaction and the storm of cytokine, followed by
multiple organ injury and also led to numbers of diseases. In
patients with extreme/basic SARS-CoV-2 have investigated
and indicated more circulatory degrees of cytokines in pro-
inflammatory conditions [23, 24]. SARS-CoV-2 has been
revealed a couple of months ago, and it is too soon to antic-
ipate the drawn-out result of patients recouping from the
illness. In any case, some significant messages may be
brightened by past encounters with SARS because of
SARS-CoV, which imparts impressive similitude to
COVID-19 [25, 26]. It was accounted that among patients
recovering from SARS, 68% kept on having lipid metabo-
lism (digestion) variations from the norm at 12-year devel-
opment; cardiovascular anomalies were available in 40%
and glucose digestion changes in 60% [27]. Comparable dis-
coveries have additionally been accounted in patients recu-
perating from other respiratory diseases [28]. In view of this,
careful adherence to those recuperating from current
COVID-19 will likewise be critical to comprehend the
drawn-out impacts of the illness and to shield these patients
from future cardiovascular diseases (CVD). In myocardial
infarction, increased cardiac troponin or electrocardiograph-
ic abnormalities were present in 7.2% in a study [29], while
other studies have shown elevated cardiac biomarker as 20%
[30]. The current study has basically focused on the compli-
cations due to COVID-19 in the cardiovascular patients.
Data has been illustrated in this manuscript for correlation
between COVID-19 and cardiovascular disorder, i.e., heart
failure, myocardial breakdown, and arrhythmia. Also, the
effect of SARS-CoV-2 has been observed highly in cardio-
vascular disease patients rather than in the patients with other
pre-existing disorders.
Viability of SARS-CoV-2 and Symptoms
SARS-CoV-2 spreads prevalently through respiratory aero-
solized beads and oral droplets and additionally can be recog-
nized in the stool [31]. Transmission may happen from both
symptomatic and asymptomatic patients, with auxiliary con-
tamination rates extending 0.5–5% [32]. The SARS-CoV-2
has been shown to stay stable for 3 h in the aerosolized struc-
ture, as long as 1 day on cartoon and upwards of 72 h on
plastic sheets, treated metals, and steels [33]. The median in-
cubation time ranged between 4 and 5 days, extended to
14 days, and the 97.5% participation indication was noticed
within 276 h of exposure [34, 35]. The most common indica-
tions of SARS-CoV-2 are normal pyrexia and mild fatigue;
however, critical symptoms are like severe fatigue, pneumo-
nia, and multiple organ and cardiovascular issues (Table 1)
[21, 32, 36]. The case mortality rate was 6% among COVID-
19 patients with hypertension, 7.3% with diabetes, and 10.5%
with CVD, but the total cases are 2.3% [37].
Incidence of SARS-CoV-2 with CVD
The significant data of case fatality rate (CFR) around the
world perspective to coronavirus, SARS, and MERS are sum-
marized in Table 2 [29, 38, 39]. The data reported on 21
March 2020 showed that the case fatality rate varies greatly
by country to country, geographical locations, age, and sex of
patients (Table 3) [30]. The relations between total cases of
COVID-19 on 12 May 2020 with case fatality rate and 21
March 2020 worked out (Table 4). The case fatality rate ex-
ponentially increases with age (Table 5 and Fig. 2) and sever-
ity of the diseases stated in a report from China (Table 6) [40].
There is an increased vulnerability in patients of SARS-CoV-
2 with a previous history of cardiovascular disease and allied
more severe diseases leading to worse clinical outcomes [7,
23, 41, 42]. Different CVD chance factors likewise unfavor-
ably influence the sickness of these patients, in spite of the fact
that they do not improve the probability of building up a
contamination.
In China, the 1527 patients of SARS-CoV-2 were assessed
and of them, 9.7% revealed pervasiveness of diabetes, 16.4%
of cardio-cerebrovascular malady, and 17.1% of hypertension
[7]. In spite of the fact that the commonness of hypertension as
well as diabetes in this companion was like everyone of
China, the pervasiveness of cardio-cerebrovascular sickness
was a lot higher. The Chinese Center for Disease Control
and Prevention depicted the colossal report of clinical results
in 44,672 affirmed instances of COVID-19 and 6% of hyper-
tension, 7.3% of diabetes, and 10.5% of CVD, but the overall
cases are 2.3%which was the case fatality rate [42]. However,
data are lacking for different geographic locations that can
vary the outcome of clinical effects and prevalence of different
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cardiovascular comorbidities. Outside Hubei Province and
different states of China, in Asian countries, the CFR is re-
corded lower, but in some European countries and the USA
including Washington, it is much higher [27, 40]. The comor-
bidities were typical in this associate, congestive cardiovascu-
lar breakdown in 42.9% cases. In 33.3% of patients, intense
cardiovascular brokenness occurred and approximately 52.4%
patients died. However except certain extreme cases, in gen-
eral case fatality rate in the United States is by all accounts a
lot of lower i.e. 201 passing out of 15,219 affirmed cases [42].
Despite the fact, it is probably going to ascend the same num-
bers of patients as of now hospitalized and have not yet had
the unmistakable result [27, 28]. So, the cardiovascular prob-
lems in SARS-CoV-2 are mainly acute cardiac injury, heart
failure, arrhythmia, and potential long-term consequences
(Fig. 3) [12, 43].
Myocardial Infarction and SARS-CoV-2
Various informational indexes now confirm the expanded
hazard for bleak and mortal entanglements due to COVID-
19 among individuals with previous cardiovascular malady
history including hypertension, coronary course infection,
and heart failure [44]. These striking perceptions have
strengthened preventive strategies and without a doubt have
brought about its spared. In spite of the fact, scenes of clinical
myocarditis have been suspected and a couple of cases have
been accounted in earlier investigations of three heart associ-
ations as the SARS-CoV-2 has been hard to affirm [45]. Acute
myocardial (coronary) infarction is usually portrayed as car-
diovascular complexity in SARS-CoV-2. Various data have
utilized several explanations for acute myocardial infarction,
remembering ascends for cardiovascular catalyses or poten-
tially electrocardiographic variations from the norm. As high
as it may be, the elevation of high-efficacy cardiac troponin-I
above the 99th percentile top remarked range is the most com-
monly used definition. The general recurrence of cardiovas-
cular infarction has been variable, yet roughly positive cases
are 8–12% which is known to make critical tallness of cardiac
troponin-I [30]. The recently referenced assessment of the
China’s population examinations uncovered 8% recurrence
of extraordinary cardiovascular infarction in patients with rea-
sonable outcome at 17% rate of cardiac troponin-I rise [7, 22].
In spite of the certifiable rate, acute cardiovascular infarction
has been dependably exhibited a solid negative disease marker
in patients of COVID-19 [23, 41]. Patients with ICU or
serious/lethal sickness are bound to have some wrinkle of
Table 1 COVID-19’s symptoms with cases in China
Symptoms Sub-symptoms Infra-symptoms Range (%) Ref.
Most common Normal fever 87.9 [32]
Production of spit 33.4 [32]
Difficulty breathing 18.6 [32]
Pharyngitis 13.9 [32]
Cough (Dry) 67.7 [36]
Fatigue 38.1 [32]
Rhinorrhea 4.8 [36]
Gastro-intestinal problems Emesis/nausea 5 [36]
Diarrhea 4–14 [36]
Mild No pneumonia/mild pneumonia 81 [21]
Severe Dyspnea (respiratory rate ≥ 30/min) 14 [21]
Saturation blood oxygen ≤ 93 [21]
Arterial oxygen partial pressure < 300 for fraction of induced oxygen ratio Incubation time is 24 to 48 h > 50 [21]
Delicate Failure in respiratory, multiple organ dysfunction or failure 5 [21]
Table 2 Case fatality rate in significantly different pandemic around the world
Types Range (%) Ref.
China’s original reports suggested CRF 2.3 [37]
Fatal risk of symptomatic case (likely to die after developing symptoms) was estimated with subsequent reports 1.4 [33]
Contrasts with influenza 0.1 [33]
MERS 34 [33]
SARS 10 [33]
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troponin rise. On the other hand, recurrence of raised cardiac
troponin is lower (only 1–2%) in patients with kind-hearted
malady who do not require intensive care unit (ICU) affirma-
tion. Intense heart injury can happen in any of the systems
depicted above, and there might be an expansion in cardiovas-
cular troponin in SARS-CoV-2 patients. The general occupa-
tion of different components has not been delineated anyway
prompt myocardial infarction (for instance non-coronary) be-
cause of an inflammatory disease of the heart muscle (myo-
cardium), i.e., myocarditis. During an episode of Toronto
SARS, the observations maintained by a past assessment
move patients killed due to myocarditis association [46].
Just a single Chinese investigation revealed the rate of cardio-
vascular breakdown in the patients of SARS-CoV-2 [22]. The
52% of patients were suffering from cardiovascular break-
down and thusly died; however, 12% patients released from
the hospital or clinic. Evidence of hospitalized patients for
SARS-CoV-2 is normal in myocardial infarction; however,
the reasons for myocardial infarction have not been elucidat-
ed, and its contribution to the occurrence of heart failure is not
well characterized.
The recurrence of hospitalized patients with COVID-19 is
different among myocardial infarction as reflected by height
in troponin levels with revealed frequencies 7–28% [33–35].
A few investigations have distinguished more prominent re-
currence and size of troponin elevations in hospitalized pa-
tients with extreme ailment and more awful results [41].
Information is missing on the recurrence of troponin heights
in asymptomatic or just mildly symptomatic COVID-19 pa-
tients. About 19.7% of the COVID-19 patients who have
high-sensitivity troponin-I were admitted to a hospital in
Wuhan, China [47]. Patients with this scar of myocardial in-
farction were more established and had more comorbidities
including chronic heart failure in 14.6% versus 1.5% and
greater laboratory abnormalities like higher levels of aspartate
aminotransferase, procalcitonin, and C-reactive protein and
also more lung radiographic abnormalities, and more compli-
cations compared with those without myocardial infarction
[47]. The mortality rate was also higher with myocardial in-
farction (51.2% vs. 4.5%) [48]. The risk of death at symptom
onset was four times higher in patients with evidence of myo-
cardial infarction at admission.
The other study in Wuhan showed that elevations in
high-sensitivity troponin-I and more than 99th percentile
top remarked limit threshold were identified upon admis-
sion in 46% non-survivors versus 1% survivors [22]. In
contrast, a study of 24 critically ill COVID-19 patients in
Seattle found elevated troponin levels after intensive care
unit admission in only 13 (15%) of tested patients, with
50% mortality rate [49]. Some differences in the frequency
of troponin augmentation may be due to the use of different
troponin assays and differences in patient populations. Only
one study was assessed and found that the patients with
proof of myocardial infarction have a greater spreading of
heart disease and cardiovascular risks compared with hy-
pertensive biomarkers [47]. In this way, it is not yet con-
ceivable to decide if myocardial infarction is an indepen-
dent risk marker in COVID-19 or if the hazard related with
it is identified to the weight of previous cardiovascular
sickness.
Heart Failure and COVID-19
Restricted information is accessible on the frequency of
SARS-CoV-2 with pre-existing heart failure patients. In a re-
view report on 799 hospitalized COVID-19 patients in
Wuhan, China, with pre-existing heart failure, it was reflected
that 49% patients died, 3% patients recuperated, and 1% pat-
tern predominance of constant chronic heart failure in the
Table 4 Relation between total cases of COVID-19 on 12 May 2020
with CFR on 21 March 2020
Country CFR on 21 March 2020 Total cases on 12 May 2020
China 81,304 82,920
Italy 47,021 222,618
Iran 20,610 112,248
Spain 25,374 270,897
South Korea 8779 10,963
Germany 21,828 173,766
USA 22,043 1,431,438
Table 3 Based on data reported from 21 March 2020, the CFR varies
greatly by country
Country Cases (%) Number of cases Reference
China 4.0 81,304 [35]
Italy 0.6 47,021 [35]
Iran 7.5 20,610 [35]
Spain 5.4 25,374 [35]
South Korea 1.2 8779 [35]
Germany 0.3 21,828 [35]
USA 1.3 22,043 [35]
Table 5 CFR exponentially increases with age (China’s report)
Ages CFR in % Reference
0–50 years old < 1 [37]
50–59 years old 1.3 [37]
60–69 years old 3.6 [37]
70–79 years old (septuagenarians) 8 [37]
80–89 years old (octogenarians) 14.8 [37]
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combined groups [50]. In an investigation of 191 patients
hospitalized in two different medical centers in Wuhan, heart
failure was recognized in patients who died, i.e., 52%, and
who recuperated, i.e., 12% patients [22]. The occurrence of
acute heart failure was not archived in some arrangement of
hospitalized COVID-19 patients and raised natriuretic peptide
has been identified, especially in patients with proof of heart
injury. In the above-mentioned series of 416 hospitalized pa-
tients, NT-proBNP levels were significantly lesser in patients
without elevated troponin ranges than in patients with tropo-
nin elevation (139 vs. 1689 pg/ml) [47].
Cardiovascular-related diseases and its risk factors are
exceptionally common in SARS-CoV-2 hospitalized pa-
tients [7]. For instance, in a data of 191 patients hospitalized
in Wuhan, comorbidities included 30% hypertension, dia-
betes mellitus in 19%, and coronary heart disease in 8%
[22]. Patients with a known history of heart failure may
have an acute decompensation due to the development of
COVID-19 disease [51]. Particularly the prevalence of car-
diovascular diseases and heart disease in general varies
from population to population [22, 41]. Thus, in patients
diagnosed with COVID-19 diagnosed, there is a broad cat-
egory for prevalent cardiovascular diseases. Rates have
been reported between 4.2 and 25%, with most of China’s
[50, 52] range. The percentage is higher among patients
admitted to intensive care units or who died [50]. In one
investigation, 22.7% of all fatal case patients participate
with preliminary cardiac and heart-related diseases, and
the case fatality rate was 10.5% [53]. The jobs of ACE2
articulation in SARS-CoV-2 pathogenesis and human
COVID-19 helplessness are to a great extent obscure.
Since SARSCoV-2 uses ACE2 as the receptor, it is intelli-
gent to expect that every single human cell that expresses
ACE2 are the likely focuses for SARSCoV-2 [54]. In this
way, the accompanying inquiries with respect to ACE2 ar-
ticulation comparable to COVID-19 defenselessness can be
asked [55, 56]: (a) Which parts of the body express ACE2?
(b) Which ACE2-communicating organs are inclined to
SARS-CoV-2 contamination? (c) Is higher articulation lev-
el of ACE2 equivalent to more prominent COVID-19
helplessness?
Case Fatality Rate and COVID-19 Patients
With Cardiovascular Disease
There is considerable proof of a relationship between car-
diovascular disease hazard variables of hypertension, dia-
betes, cardiovascular diseases, and the hazard and serious-
ness of COVID-19 contamination [52, 57]. The accompa-
nying observational investigations represent the greatness
of the relationship [40, 58]. There are 169 emergency
Table 6 CFR increases with the severity of the diseases (China’s report)
COVID-19 symptoms Disease symptoms CFR (%) Ref.
Mild or severe cases - No death [37]
Critical patients - 49 [37]
Patients with no comorbidities - 0.9 [37]
Patients with medical comorbidities Cardiovascular disease (CVD) 10.5 [37]
Diabetes mellitus (DM) 9.2 [37]
Chronic obstructive pulmonary disease 6.3 [37]
Hypertension 6 [37]
Cancer 7.6 [32]
Chronic respiratory disease 8.0 [32]
Fig. 2 Trends of case fatality rate
and its correlation to age of
patients (Source: China’s report)
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clinics in Asia, Europe, and North America by using inspec-
tion database from the correlation between standard cardiac
and heart-related diseases, and hospital deaths were
assessed among patients hospitalized with SARS-CoV-2
[59]. Out of total 8910 COVID-19 patients, 94.21%, i.e.,
8395 patients, survived and were discharged, and 5.78%,
i.e., 515 patients, died in the hospital. Baseline cardiovas-
cular diseases comparative with no contamination were au-
tonomously connected with an expanded danger in hospital
(medical clinic) demise (10.2% vs. 5.2%; chance proportion
2.70; 95%; cardiac infraction, CI 2.08–3.51%). The
Chinese Center for Disease Control and Prevention report-
ed on 11 February 2020 that about 72,314 cases and 44,672
active cases were confirmed and the crude mortality rate
recorded was 2.3% [60]. For those octogenarians (a person
who is between 80 and 89 years old) or above ages, the case
fatality rate was 14.8% [26, 60]. History of coronary and
heart diseases was available in 4.2% everything being
equal, however in 22.7% of lethal cases. The case fatality
rate among patients with coronary and heart diseases was
10.5%. Another report assessed 1099 cases from 30 terri-
tories inside terrain China [34]. Among them, 15.7% were
classified as severe illness and a primary endpoint, while
6.1% defined as dead or intensive care unit admission with
mechanical ventilation. The presence of coronary heart dis-
eases (non-critical disease vs. critical, i.e., 1.8% vs. 5.8%,
and primary endpoint vs. no primary endpoint, i.e., 9% vs.
2%) was consistently higher between patients with critical
illness versus non-critical illness and patients with primary
endpoint versus primary endpoint. The 191 patients from
Wuhan Province diagnosed before 31 January 2020 showed
significant inseparable associations with the outcome of
death for coronary hear t diseases (24% vs. 1%,
p < 0.0001) [12].
Another study found that the occupancy of intense injury
controlled by troponin elevation was a noteworthy factor in
the relation of cardiovascular disease mortality [61]. Among
the 187 patients infected with SARS-CoV-2, 66 (35%) had
cardiovascular diseases (marked as coronary heart diseases, hy-
pertension, or cardiomyopathy) in background, and troponin
was raised in 52 (28%) patients. Troponin elevation was iden-
tified as more frequent in patients with cardiovascular diseases
(55%, i.e., 36 of 66). The mortality rate in patients with chronic
kidney disease and elevated troponin was 69% (i.e., 25 of 36).
Mortality rate in patients without cardiovascular diseases and
normal troponin was 7.6%, normal troponin and cardiovascular
disease with 13.3%, advanced troponin and without cardiovas-
cular disease with 37.5%, and 69.4% between cardiovascular
diseases and advanced troponin (Table 7) [28]. Moreover, tro-
ponin elevation corresponded with rises in C-responsive pro-
tein, and higher troponin raises anticipated higher mortality.
Although interpretation is included in the number of patients,
there is a suggestion that patients with underlying cardiovascu-
lar diseases (including hypertension) have an increased risk of
acute injury and worsening survival in the event of injury. The
reason for this relationship and whether injury increases the risk
for myocardial infractions or myocarditis will require additional
investigation. COVID-19 is the pandemic disease globally and
currently it has led to death of several people across worldwide
[62]. The most patients affected with this disease are of cardio-
vascular obligations, which include heart failure, myocardial
breakdown, and arrhythmia. It has been observed that the pa-
tients with pre-cardiovascular disease develop new cardiac dis-
orders in the patients affected with SARS CoV-2 [62]. Further
research as well as clinical trials is going on for the study of
mechanism, effect, and treatment of COVID-19, also for com-
bating the effect of SARS-CoV-2 in patients with cardiovascu-
lar diseases.
Fig. 3 Cardiovascular problems
in COVID-19 patients
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Conclusions
SARS-CoV-2 is spreading prevalently through respiratory
beads, yet in addition can be aerosolized or recognized in
the stool. Transmission may happen from both symptomatic
and asymptomatic patients, with auxiliary contamination rates
extending 0.5–5%. The case fatality rate was 6% of hyperten-
sion, 7.3% of diabetes, and the 10.5% of cardiovascular dis-
eases, but the overall cases were 2.3%. The mortality rates in
an investigation of 191 patients hospitalized in two different
medical centers in Wuhan were recorded as 52% associated to
heart failure; however, 12% recovered and came back to
home. Another study found that the occupancy of intense
injury controlled by troponin elevation was a noteworthy fac-
tor in the relation of cardiovascular disease mortality. The 187
patients infected by SARS-CoV-2 showed 35% cardiovascu-
lar disease backgrounds, and 28% with raised troponin.
Troponin elevation was identified as more frequent in patients
with cardiovascular diseases, i.e., 55%. Mortality rate in pa-
tients without cardiovascular diseases and normal troponin
was recorded as 7.6%, normal troponin and cardiovascular
disease with 13.3%, advanced troponin and without cardio-
vascular disease with 37.5%, and 69.4% among cardiovascu-
lar disease with raised troponin situation. We can conclude
that the effect of SARS-CoV-2 in cardiovascular disease pa-
tients is dangerous and the most common risk factor and
health challenge for up to septuagenarians and octogenarians
in the current pandemic situation.
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